AM Press ReleasesMedicalPersonalized MedicineProsthetics

BellaSeno starts clinical trials of resorbable chest and breast implants

The first trial is expected to enroll 10 patients with pectus excavatum, a common congenital chest wall deformity in which the breastbone is sunken into the chest.

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

BellaSeno GmbH, an ISO 13485-certified MedTech company developing resorbable chest and breast implant scaffolds using additive manufacturing technologies, began two clinical trials of its products in Australia, which are sponsored by its Australian subsidiary BellaSeno Pty. Already, recruiting has started in Brisbane, Australia.

The first trial is expected to enroll 10 patients with pectus excavatum, a common congenital chest wall deformity in which the breastbone is sunken into the chest. The principal investigator of this trial is Dr. Michael Wagels, Director of the Herston Biofabrication Institute (HBI), Specialist Plastic and Reconstructive Surgeon at the Princess Alexandra Hospital, Director of the Australian Centre for Complex Integrated Surgical Solutions (ACCISS) and Senior Lecturer at the University of Queensland. BellaSeno already published first-in-human data in 2021, demonstrating that its implant was able to camouflage a pectus excavatum defect not reconstructable by conventional techniques.

The second trial aims to enroll 20 patients who either need breast implant revision or surgery to correct congenital breast defects. The principal investigator of the second trial is Prof. Owen Ung, Director of the Comprehensive Breast Cancer Institute (CBCI), a consultant breast surgeon at the Royal Brisbane and Women’s Hospital and Professor of Surgery, University of Queensland, Australia.

BellaSeno GmbH, a company developing resorbable breast implant scaffolds using AM, began two clinical trials of its products in Australia

In both trials, patients will receive porous polycaprolactone implants produced in Bellaseno’s AI-driven additive manufacturing facilities by a no-touch approach. Polycaprolactone has been used in healthcare for decades as absorbable suture material. Once the implants are inserted in compressed form by minimally invasive surgery, the structure unfolds and is subsequently grafted with the patient’s own fat tissue obtained by liposuction. Within up to 5 years, the polycaprolactone scaffold is fully absorbed and replaced by fat cells, leaving no permanent remnants of foreign material in the body. This scaffold-guided tissue reconstruction (SGTR) provides a promising alternative to silicone or other permanent implants. The Company´s novel implants are designed to ultimately result in natural tissue.

The primary outcome of the trials will be intra- and post-operative device safety; secondary endpoints are adverse event rate and frequency of complication. Secondary endpoints comprise, among others, change in (fat) volume and soft tissue retention as well as pain and quality of life.

“This trial is a very important step for us to demonstrate that our approach is not only safe but leads to substantial improvements in terms of long-term safety, health and quality of life,” said Dr. med. Tobias Grossner, CMO of BellaSeno. “We very much hope the trials once more confirm our scaffold-guided tissue reconstruction concept.”

“We are delighted to spearhead the administration of novel, fully absorbable implants for soft tissue reconstruction applications. There is a clear need for ​a safe alternative to contemporary alloplastic materials and operative techniques in pectus excavatum and breast surgery. Having customizable implants that resorb, leaving behind the patient’s own tissues, is a big step forward,” said Dr. Michael Wagels, Principal investigator of the pectus excavatum trial.

“It is important to us that patients have access to healthier alternatives to permanent implants. There is a strong demand for restoring fully natural breast tissue without potentially risky remnants in the body. We believe that BellaSeno´s solutions can play an important role in addressing these needs,” added Prof. Owen Ung, Principal investigator of the breast trial.

Research 2022
Polymer AM Market Opportunities and Trends

This new market study from 3dpbm Research provides an in-depth analysis and forecast of the three core segm...

3D Printing Media Network

3D Printing Media Network is the online trade media portal published by 3dpbm, a leading marketing and market research firm specializing in the AM industry. 3dpbm also publishes the 3D Printing Business Directory, the AM Focus eBook series and the 3dpbm Research AM Market Reports. 3D Printing Media Network was founded with the goal to provide the latest industry news, insights and opinions to a global audience of professionals and decision makers.

Related Articles

Back to top button

We use cookies to give you the best online experience and for ads personalisation. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services

STAY AHEAD

OF THE CURVE

Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*

WELCOME ON BOARD!